Exogenous Melatonin for Delirium Prevention: a Meta-analysis of Randomized Controlled Trials
- 1.8k Downloads
Recently, two high-quality clinical randomized controlled trials (RCTs) regarding the preventive effect of exogenous melatonin on delirium drew inconsistent conclusions. We therefore performed a systemic review to explore whether melatonin had a benefit on delirium prevention. MEDLINE, EMBASE, and Cochrane Library were searched from January 1980 to April 2015 for English language studies. After strict selection and evaluation, the data were extracted from the included four RCTs. The primary outcome of this meta-analysis was the incidence of delirium. The secondary outcome was the improvement of sleep–wake rhythm. A total of four RCTs with 669 elderly patients were included in the present study. Melatonin group showed a tendency to decrease the incidence of delirium (relative risk [RR] 0.41, 95 % confidence interval [CI] 0.15 to 1.13; P = 0.08) compared with control group. In subgroup analysis of the elderly patients in medical wards, melatonin supplementation decreased the incidence of delirium by 75 % (RR 0.25, 95 % CI 0.07 to 0.88; P = 0.03), but not in sleep–wake disturbance (RR 1.24, 95 % CI 0.51 to 3.00; P = 0.64). No differences were found in the incidence of delirium between the two groups in the elderly patients that were presented to surgical wards. In conclusion, melatonin supplementation had a significant preventive effect in decreasing the incidence of delirium in elderly patients that were presented to medical wards. Further studies should provide sufficient evidence about the effect of melatonin on delirium in a large sample size.
KeywordsDelirium Melatonin Sleep–wake cycle Meta-analysis
This study was supported by National Natural Science Foundation of China (No. 81171096 and No. 81371433) to JM Zhang and National Natural Science Foundation of China (No. 81271273) to Q Wu.
Conflict of interest
The authors report no financial or other relationship relevant to the subject of this article.
- 29.de Jonghe A, van Munster BC, Goslings JC, Kloen P, van Rees C, Wolvius R, van Velde R, Levi M et al (2014) Effect of melatonin on incidence of delirium among patients with hip fracture: a multicentre, double-blind randomized controlled trial. CMAJ: Can Med Assoc J 186(14):E547–E556. doi: 10.1503/cmaj.140495 CrossRefGoogle Scholar
- 32.Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700. doi: 10.1136/bmj.b2700 CrossRefPubMedPubMedCentralGoogle Scholar
- 33.Shi L, Pu J, Xu L, Malaguit J, Zhang J, Chen S (2014) The efficacy and safety of cilostazol for the secondary prevention of ischemic stroke in acute and chronic phases in Asian population- an updated meta-analysis. BMC Neurol 14(1):251. doi: 10.1186/s12883-014-0251-7 CrossRefPubMedPubMedCentralGoogle Scholar
- 37.Buscemi N, Vandermeer B, Hooton N, Pandya R, Tjosvold L, Hartling L, Vohra S, Klassen TP et al (2006) Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: meta-analysis. BMJ 332(7538):385–393. doi: 10.1136/bmj.38731.532766.F6 CrossRefPubMedPubMedCentralGoogle Scholar
- 43.Garcia JJ, Lopez-Pingarron L, Almeida-Souza P, Tres A, Escudero P, Garcia-Gil FA, Tan DX, Reiter RJ et al (2014) Protective effects of melatonin in reducing oxidative stress and in preserving the fluidity of biological membranes: a review. J Pineal Res 56(3):225–237. doi: 10.1111/jpi.12128 CrossRefPubMedGoogle Scholar